Comparative Pharmacology
Head-to-head clinical analysis: CORVERT versus ETHMOZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORVERT versus ETHMOZINE.
CORVERT vs ETHMOZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibutilide, a class III antiarrhythmic agent, prolongs atrial and ventricular refractoriness by blocking delayed rectifier potassium current (IKr) and activating slow inward sodium current (INa-S).
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
1 mg intravenously over 10 minutes; repeat once after 10 minutes if conversion to sinus rhythm not achieved. Maximum total dose: 2 mg.
200-300 mg orally every 8 hours; maximum 900 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours (range 2–12 hours) in patients with normal renal function. Prolonged in renal impairment (up to 16 hours in severe impairment).
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Renal (approximately 82% of total clearance), with about 18% biliary/fecal elimination. Mostly unchanged drug and metabolites.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Category C
Category C
Antiarrhythmic
Antiarrhythmic